@article{76bcbcf839c447b4a1ff4a6abcc6d55a,
title = "Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer",
keywords = "BCG failure, BCG naive, Intravesical therapy, Non–muscle invasive bladder cancer",
author = "Bree, {Kelly K.} and Brooks, {Nathan A.} and Kamat, {Ashish M.}",
note = "Funding Information: A.M. Kamat has served as a consultant or sat on the advisory board of the following: Abbott Molecular, Arquer, ArTara, Asieris, Astra Zeneca, BioClin Therapeutics, BMS, Cepheid, Cold Genesys, Eisai, Engene, Inc, Ferring, FerGene, Imagin, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara, Roviant, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, and US Biotest. He has received grant funding or research support from: Adolor, BMS , FKD Industries , Heat Biologics , Merck , Photocure , SWOG/NIH , SPORE , and AIBCCR . Funding Information: A.M. Kamat has served as a consultant or sat on the advisory board of the following: Abbott Molecular, Arquer, ArTara, Asieris, Astra Zeneca, BioClin Therapeutics, BMS, Cepheid, Cold Genesys, Eisai, Engene, Inc, Ferring, FerGene, Imagin, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara, Roviant, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, and US Biotest. He has received grant funding or research support from: Adolor, BMS, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH, SPORE, and AIBCCR.",
year = "2021",
month = jun,
doi = "10.1016/j.hoc.2021.02.003",
language = "English (US)",
volume = "35",
pages = "513--529",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",
}